Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Sym022 |
| Synonyms | |
| Therapy Description |
Sym022 is a monoclonal antibody that targets LAG3 and inhibits binding of MHC II molecules to increase cytokine production by T-cells and prevent tumor growth (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5626). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Sym022 | Sym 022|Sym-022 | Immune Checkpoint Inhibitor 150 LAG3 Antibody 19 | Sym022 is a monoclonal antibody that targets LAG3 and inhibits binding of MHC II molecules to increase cytokine production by T-cells and prevent tumor growth (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5626). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03489369 | Phase I | Sym022 | Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas | Completed | USA | CAN | 0 |